FENOFIBRATE Tablet Ref.[51352] Active ingredients: Fenofibrate

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2020  Publisher: Genus Pharmaceuticals Limited, T/A Genus Pharmaceuticals, Linthwaite, Huddersfield, HD7 5QH, UK

4.1. Therapeutic indications

Fenofibrate 160 mg Tablets are indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:

  • Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
  • Mixed hyperlipidaemia when a statin is contraindicated or not tolerated.
  • Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL cholesterol are not adequately controlled.

4.2. Posology and method of administration

Posology

Adults

The recommended dose is one tablet containing 160 mg fenofibrate taken once daily. Patients currently taking one fenofibrate 200mg capsule can be changed to one fenofibrate 160 mg tablet without further dose adjustment.

Elderly patients (≥65 years old)

No dose adjustment is necessary. The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate <60 mL/min/1.73 m² (see Patients with renal impairment).

Patients with renal impairment

Fenofibrate should not be used if severe renal impairment, defined as eGFR <30 mL/min per 1.73 m², is present.

If eGFR is between 30 and 59 mL/min per 1.73 m², the dose of Fenofibrate should not exceed 100 mg standard or 67 mg micronized once daily.

If, during follow-up, the eGFR decreases persistently to <30 mL/min per 1.73 m², Fenofibrate should be discontinued.

Paediatric population

The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established. No data are available. Therefore the use of fenofibrate is not recommended in paediatric subjects under 18 years.

Hepatic disease

Patients with hepatic disease have not been studied.

Dietary measures initiated before therapy should be continued.

If after several months of fenofibrate administration (e.g. 3 months) serum lipid levels have not been reduced satisfactorily, complementary or different therapeutic measures should be considered.

Method of administration

Tablets should be swallowed whole during a meal.

4.9. Overdose

No case of overdosage has been reported. No specific antidote is known. If an overdose is suspected, treat symptomatically and institute appropriate supportive measures as required. Fenofibrate cannot be eliminated by haemodialysis.

6.3. Shelf life

36 months.

6.4. Special precautions for storage

No special precautions for storage.

6.5. Nature and contents of container

Blister strips (PVC/PVDC – Aluminium).

Boxes of 10, 20, 28, 30, 50, 84, 90, 98 and 100 tablets.

Hospital pack sizes: 280 and 300 tablets.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

No special requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.